Founder: Susan Catalano

Scale: Jenny Petering (Director of Australian subsidiary)

Cognition Therapeutics (“CogRx”) is a clinical stage pharmaceutical company working on the discovery and development of small molecule therapeutics acting on novel targets to halt disease progression and improve symptoms in neurodegenerative disorders, including Alzheimer’s disease. Founder Susan Catalano is an expert in synaptic plasticity, memory and learning, Alzheimer’s disease and the biology of protein oligomers, the toxic shapes of protein that underlie many neurodegenerative diseases. CogRx is currently in clinical trials with its first-in-class Alzheimer’s drug; a drug designed to rapidly reverse cognitive decline and halt disease progression in patients diagnosed with mild to moderate Alzheimer’s disease.